{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:13:33Z","timestamp":1794111213404,"version":"4.8.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Thrombosis is a major contributor to global morbidity and mortality. Current standards of care target the extrinsic and\/or common pathways of coagulation, effectively inhibiting thrombosis but also increasing bleeding risk, highlighting the unmet need for additional treatment options. Genetic deficiency in factor XI (FXI), a component of the intrinsic pathway, reduces thrombosis risk without spontaneous bleeding. We generated 2 FXI monoclonal antibodies (mAbs) with distinct profiles to provide new approaches to anticoagulation. Cenvacibart (REGN7508Cat) targets the catalytic domain to completely block FXI activity (induced by activated FXII [FXIIa] or activated FXI [FXIa] in the intrinsic pathway or thrombin in the intrinsic\/common pathway amplification loop), thereby maximizing anticoagulation. Amrecibart (REGN9933A2) targets the apple 2 domain of FXI\/FXIa to specifically prevent FXI activity induced by FXIIa, delivering perhaps less anticoagulation but with potentially lower bleeding risk. We evaluated the anticoagulant effects of both mAbs in vitro in human and nonhuman primate plasma, in vivo in nonhuman primates, and healthy volunteers. Both mAbs inhibited intrinsic pathway\u2013triggered coagulation, assessed by activated partial thromboplastin time (aPTT); cenvacibart exhibited a greater increase in aPTT vs amrecibart or other FXI-targeted inhibitors. Neither amrecibart nor cenvacibart affected the extrinsic pathway, assessed by prothrombin time (PT). In nonhuman primates, both mAbs prevented thrombosis without increasing bleeding. In first-in-human studies, both mAbs were generally well tolerated and dose-dependently inhibited intrinsic pathway\u2013triggered coagulation, with durable aPTT prolongation without affecting PT. Amrecibart and cenvacibart may offer tailored therapies for patients with different bleeding risk profiles. These trials were registered at www.clinicaltrials.gov as NCT05102136 and NCT05603195.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032276","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:53:07Z","timestamp":1781196787000},"page":"1867-1879","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Anticoagulation with the mechanistically distinct FXI\/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)"],"prefix":"10.1182","volume":"148","author":[{"given":"Dan","family":"Chalothorn","sequence":"first","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Kithcart","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Marin","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Somersan-Karakaya","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KehDih","family":"Lai","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Cauwberghs","sequence":"additional","affiliation":[{"name":"2SGS, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ackroyd","sequence":"additional","affiliation":[{"name":"3Fortrea Clinical Research Unit, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7844-7537","authenticated-orcid":false,"given":"Kusha","family":"Mohammadi","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5945-841X","authenticated-orcid":false,"given":"Anju","family":"Shrestha","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4078-7242","authenticated-orcid":false,"given":"Ashique","family":"Rafique","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Saotome","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1482-0136","authenticated-orcid":false,"given":"Matthew C.","family":"Franklin","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Murphy","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6254-0641","authenticated-orcid":false,"given":"William","family":"Olson","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Olenchock","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4433-6529","authenticated-orcid":false,"given":"Gary A.","family":"Herman","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gutstein","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Sirulnik","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5214-5784","authenticated-orcid":false,"given":"Lori G.","family":"Morton","sequence":"additional","affiliation":[{"name":"1Regeneron Pharmaceuticals, Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2026100811213155700_bib1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ Res"},{"issue":"5","key":"2026100811213155700_bib2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/ATVBAHA.124.320151","article-title":"Global health burden of venous thromboembolism","volume":"44","author":"Wendelboe","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7181","key":"2026100811213155700_bib3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatments for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"issue":"10","key":"2026100811213155700_bib4","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.12698","article-title":"Thrombosis: a major contributor to the global disease burden","volume":"12","author":"Raskob","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2026100811213155700_bib5","volume-title":"StatPearls","author":"Ashorobi","year":"2024"},{"issue":"3","key":"2026100811213155700_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(03)00324-7","article-title":"Cardioembolic stroke: an update","volume":"2","author":"Ferro","year":"2003","journal-title":"Lancet Neurol"},{"issue":"8","key":"2026100811213155700_bib7","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/jcm9082467","article-title":"Prevention of venous thromboembolism in 2020 and beyond","volume":"9","author":"Nicholson","year":"2020","journal-title":"J Clin Med"},{"key":"2026100811213155700_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev-pharmtox-032823-122811","article-title":"Oral anticoagulants beyond warfarin","volume":"64","author":"Olie","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2026100811213155700_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review","volume":"40","author":"Ballestri","year":"2023","journal-title":"Adv Ther"},{"issue":"7","key":"2026100811213155700_bib10","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3889\/oamjms.2019.289","article-title":"DOACs vs vitamin K antagonists: a comparison of phase III clinical trials and a prescriber support tool","volume":"7","author":"Pirlog","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"issue":"3","key":"2026100811213155700_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11239-013-0899-7","article-title":"Assessing bleeding risk in patients taking anticoagulants","volume":"35","author":"Shoeb","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2026100811213155700_bib12","doi-asserted-by":"crossref","first-page":"e014108","DOI":"10.1161\/JAHA.119.014108","article-title":"Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study","volume":"9","author":"Sanghai","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2026100811213155700_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ahj.2014.04.007","article-title":"Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: proceedings, Washington, DC, December 3-4, 2012","volume":"168","author":"Hess","year":"2014","journal-title":"Am Heart J"},{"issue":"10","key":"2026100811213155700_bib14","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/ATVBAHA.123.318781","article-title":"New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors","volume":"43","author":"Chan","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"2026100811213155700_bib15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","article-title":"Factor XI as a therapeutic target","volume":"36","author":"Gailani","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"2026100811213155700_bib16","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1161\/ATVBAHA.107.155952","article-title":"Intrinsic pathway of coagulation and arterial thrombosis","volume":"27","author":"Gailani","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"2026100811213155700_bib17","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1538-7836.2007.02446.x","article-title":"The intrinsic pathway of coagulation: a target for treating thromboembolic disease?","volume":"5","author":"Gailani","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2026100811213155700_bib18","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2010-02-270918","article-title":"A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo","volume":"116","author":"Cheng","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2026100811213155700_bib19","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2026100811213155700_bib20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/16078454.2022.2083482","article-title":"Phenotypic and genetic analyses of four cases of coagulation factor XII deficiency","volume":"27","author":"Li","year":"2022","journal-title":"Hematology"},{"key":"2026100811213155700_bib21","doi-asserted-by":"crossref","first-page":"2050313X221118728","DOI":"10.1177\/2050313X221118728","article-title":"Hereditary factor XII deficiency in an adult patient: a case report","volume":"10","author":"Al-Ansari","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"issue":"3","key":"2026100811213155700_bib22","doi-asserted-by":"crossref","first-page":"omaa146","DOI":"10.1093\/omcr\/omaa146","article-title":"Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients","volume":"2021","author":"Moiz","year":"2021","journal-title":"Oxf Med Case Reports"},{"issue":"1","key":"2026100811213155700_bib23","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1038\/s41467-025-62789-5","article-title":"Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis","volume":"16","author":"Haj","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"2026100811213155700_bib24","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2026100811213155700_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"9","key":"2026100811213155700_bib26","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2026100811213155700_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2516.2006.01304.x","article-title":"Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy","volume":"12","author":"Salomon","year":"2006","journal-title":"Haemophilia"},{"issue":"3","key":"2026100811213155700_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199107183250303","article-title":"Factor XI deficiency in Ashkenazi Jews in Israel","volume":"325","author":"Asakai","year":"1991","journal-title":"N Engl J Med"},{"issue":"15","key":"2026100811213155700_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.2023020721","article-title":"Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment","volume":"143","author":"Barg","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026100811213155700_bib30","doi-asserted-by":"crossref","first-page":"102860","DOI":"10.1016\/j.rpth.2025.102860","article-title":"Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis","volume":"9","author":"Godier","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"2026100811213155700_bib31","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2026100811213155700_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"23","key":"2026100811213155700_bib33","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"2026100811213155700_bib34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"2026100811213155700_bib35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"2026100811213155700_bib36","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1111\/jth.15890","article-title":"Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery\u2014systematic review and meta-analysis","volume":"20","author":"Presume","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"15","key":"2026100811213155700_bib37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N Engl J Med"},{"issue":"10519","key":"2026100811213155700_bib38","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0140-6736(25)02097-5","article-title":"Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials","volume":"406","author":"Weitz","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"2026100811213155700_bib39","doi-asserted-by":"crossref","first-page":"e002322","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"2026100811213155700_bib40","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2026100811213155700_bib41","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2026100811213155700_bib43","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/jth.14418","article-title":"Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI","volume":"17","author":"Li","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2026100811213155700_bib44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb Res"},{"issue":"23","key":"2026100811213155700_bib42","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2015-10-676122","article-title":"A novel DFP tripeptide motif interacts with the coagulation factor XI apple 2 domain","volume":"127","author":"Wong","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2026100811213155700_bib45","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2026100811213155700_bib46","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol"},{"issue":"2","key":"2026100811213155700_bib47","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cts.13148","article-title":"First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor","volume":"15","author":"Perera","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"6","key":"2026100811213155700_bib48","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026100811213155700_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1309\/AJCPQ2NJD3PXFTUG","article-title":"Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay","volume":"143","author":"Morishima","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"11","key":"2026100811213155700_bib50","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","article-title":"Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI","volume":"50","author":"Georgi","year":"2019","journal-title":"Stroke"},{"issue":"13","key":"2026100811213155700_bib51","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"9921","key":"2026100811213155700_bib52","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"2026100811213155700_bib53","first-page":"637","article-title":"Genome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels","volume":"26","author":"Sennblad","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2026100811213155700_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ajhg.2012.05.009","article-title":"Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease","volume":"91","author":"Tang","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"11","key":"2026100811213155700_bib55","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/STROKEAHA.118.022792","article-title":"Genetically determined FXI (factor XI) levels and risk of stroke","volume":"49","author":"Gill","year":"2018","journal-title":"Stroke"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/15\/1867\/2593013\/blood_bld-2025-032276-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/15\/1867\/2593013\/blood_bld-2025-032276-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:21:44Z","timestamp":1791472904000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/15\/1867\/569096\/Anticoagulation-with-the-mechanistically-distinct"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":55,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032276","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,8]]},"published":{"date-parts":[[2026,10,8]]}}}